Sponsors

Tissue analysis by artificial intelligence

Nucleai, a promising artificial intelligence (AI) start-up company in the pathology arena is making cancer diagnostics more accurate, accessible and efficient through AI-based analysis of biopsies.

Pathology is ripe for disruption, with a major shortage of pathologists coupled with an increasing demand for biopsies. Research shows that by 2030 the number of active pathologists may drop by 30% compared to 2010 levels.

Nucleai is addressing this by utilising decades of cumulative experience in AI and machine vision to work for and with pathologists, the only company to provide a comprehensive suite of solutions for cancer biopsies relating to gastrointestinal, breast and prostate analysis.

Latest Issues

IHC technical issues masterclass

UK NEQAS CPT, The Haylofts, Newcastle
13 August, 2025

37th European Congress of Pathology

ACV, Vienna, Austria
6 -10 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025